Senti Biosciences Inc

NASDAQ:SNTIUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Senti Biosciences, Inc. is a preclinical biotechnology company. The Company is developing cell and gene therapies engineered with its gene circuit platform technologies to fight challenging diseases. The Company's products include SENTI-202, SENTI-401 and SENTI-301A. It is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow. SENTI-401 for the potential treatment of colorectal cancer (CRC) and Other Solid Tumors. SENTI-301A for the potential treatment of HCC and Other Solid Tumors. Its gene circuit platform technologies are designed to be applied in a modality-agnostic manner, with applicability to natural killer (NK) cells, T cells, tumor infiltrating lymphocytes (TILs), stem cells, including induced Pluripotent Stem Cells (iPSCs) Hematopoietic Stem Cells (HSCs), in vivo gene therapy, such as adeno associated virus, and messenger ribonucleic acid.

Contact Information

Headquarters

2 Corporate Drive, First FloorSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-382-3281

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

Timothy Lu

Chief Financial Officer, Treasurer, Head - Corporate Development

Deborah Knobelman

Chief Executive Officer - GeneFab

Philip Lee

Head - Research and Development, Chief Medical Officer

Kanya Rajangam

Independent Director

Susan Berland